| Resistance of Cancer Cells to Ctl-Mediated Immunotherapy 2015 Edition Contributor(s): Bonavida, Benjamin (Editor), Chouaib, Salem (Editor) |
|
 |
ISBN: 3319178067 ISBN-13: 9783319178066 Publisher: Springer OUR PRICE: $104.49 Product Type: Hardcover - Other Formats Published: June 2015 |
| Additional Information |
| BISAC Categories: - Medical | Oncology - General - Medical | Anatomy - Medical | Pharmacology |
| Dewey: 611.018 |
| Series: Resistance to Targeted Anti-Cancer Therapeutics |
| Physical Information: 0.81" H x 6.14" W x 9.21" (1.52 lbs) 353 pages |
| Descriptions, Reviews, Etc. |
| Publisher Description: This comprehensive volume explores the latest research on the mechanisms of resistance in cancer cells to CTL-mediated immunotherapy. Chapter topics discuss cell-mediated immunity as the result of cytotoxic T-lymphocytes (CTL) directed specifically against cancer cells. In addition, the volume reviews how CTL mediate the cytotoxic activity, in large part, by the indication of apoptosis; hence, tumor cells develop anti-apoptotic mechanisms and thereby, resist CTL-induced apoptosis. In order for CTL-mediated antitumor immunotherapy to be effective, it is essential that agents directed against the resistant tumor cells sensitized cancer cells for CTL-mediated apoptosis. Examples of such agents discussed in the volume include are HDAC inhibitors, proteasome inhibitors, Bcl-2 family inhibitors, PARP, antibodies, and more. |